CPT code 81595 captures a specialized molecular diagnostic service that quantifies expression of 20 genes from a peripheral blood subfraction using real-time quantitative PCR and applies an algorithmic analysis to generate a rejection risk score for patients being evaluated for heart transplantation. This code matters nationally because it supports clinical decision-making for transplant eligibility and post-transplant management, linking advanced molecular diagnostics with algorithm-driven risk stratification.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose, typical care settings, and the payer landscape addressed. The publication summarizes expected service lines, where the test is commonly performed, and what stakeholders should know about coverage context and clinical implications.

The report provides benchmarks and policy context relevant to laboratory-directed molecular diagnostics and algorithmic reporting, discusses reimbursement and coding considerations for this type of high-complexity molecular assay, and outlines clinical context for transplant teams and laboratory services. Data not available in the input where specific payer policies, fee schedules, or associated taxonomies and ICD-10 codes would normally be detailed.